

## REVIEWER'S REPORT

Manuscript No.: IJAR-55101

**Title:** Hematological toxicity of psychotropic medications: A Case Report

### Recommendation:

Accept as it is .....Yes.....

Accept after minor revision.....

Accept after major revision .....

Do not accept (*Reasons below*) .....

### Rating

	Excel.	Good	Fair	Poor
Originality		√		
Techn. Quality		√		
Clarity		√		
Significance		√		

Reviewer Name: Professor Dr Dillip Kumar Mohapatra

### Detailed Reviewer's Report

#### 1. Strengths

##### Clear clinical relevance

Hematological toxicity due to psychotropic medications is clinically important yet under-recognized, making this case highly relevant for psychiatrists and primary care clinicians.

##### Well-documented temporal causality

The report clearly shows **two distinct neutropenia episodes** following exposure to chlorpromazine and carbamazepine, with **rapid resolution after discontinuation**, strongly supporting drug-induced causality.

##### Contribution to pharmacovigilance

Reporting the adverse reaction to pharmacovigilance adds scientific credibility and real-world clinical importance.

##### Detailed medication timeline

Dosing, sequence of medication changes, and laboratory findings are clearly described, allowing readers to follow the clinical decision-making process.

## REVIEWER'S REPORT

### **Addresses an under-reported combination**

Sequential neutropenia from two different psychotropic drug classes in the same patient is uncommon and clinically instructive.

### **Critical discussion of differential diagnosis**

Consideration of **benign ethnic neutropenia** is appropriate, and its exclusion strengthens the diagnostic clarity.

### **Use of evidence-based references**

The authors cite pharmacovigilance data and relevant epidemiological studies, strengthening the scientific validity.

## *2. Weaknesses*

### **Language and grammar issues**

Several sentences require improvement for clarity, grammar, and professional tone.

### **Missing laboratory details**

Specific hematological values (WBC, ANC at each episode) are not provided, which weakens the diagnostic strength.

### **Limited diagnostic investigations**

No mention of other causes of neutropenia being ruled out (e.g., infections, nutritional deficiencies, autoimmune markers).

### **Case flow could be clearer**

The narrative could benefit from a structured table summarizing medications, doses, and corresponding hematological values.

### **Lack of formal causality assessment**

Using a standard tool (e.g., Naranjo scale or WHO-UMC causality assessment) would strengthen the case.

## REVIEWER'S REPORT

### Discussion can be enriched

Mechanisms for drug-induced neutropenia (immunologic vs. direct marrow toxicity) are not deeply explored.

### Formatting and referencing inconsistencies

Minor reference-format issues and punctuation errors exist.

## 3. Significance of the Study

### Emphasizes the need for routine hematological monitoring

This case reinforces that not only clozapine but also chlorpromazine and carbamazepine can cause clinically significant blood dyscrasias.

### Rare sequential toxicity documentation

Demonstrates that a patient may experience multiple hematological adverse reactions to different psychotropic classes, highlighting the importance of caution when prescribing alternatives.

### Strengthens awareness of risks in specific populations

Differentiating drug-induced neutropenia from benign ethnic neutropenia is an important contribution to clinical practice, especially in African populations.

### Useful for clinical guidelines and adverse drug reaction (ADR) education

Supports existing recommendations for blood count monitoring during the first weeks of psychotropic therapy.

### Case contributes to safer prescribing practices

Shows the need for personalized medication choices and close follow-up when psychotropics with known hematological risk are prescribed.

## 4. Key Points

## REVIEWER'S REPORT

A 40-year-old man developed **neutropenia and leukopenia** after starting chlorpromazine, and a **second neutropenic episode** after switching to carbamazepine.

Hematological abnormalities resolved rapidly after discontinuation of each drug.

Temporal associations strongly support **drug-induced neutropenia** rather than benign ethnic neutropenia.

Both chlorpromazine and carbamazepine are well-known but **under-recognized** causes of bone marrow suppression.

The case highlights the **need for systematic blood count monitoring** when initiating psychotropic medications with hematologic toxicity risk.